» Articles » PMID: 37445752

The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jul 14
PMID 37445752
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the second-most-common cancer while being the leading cause of cancer deaths worldwide. It has been found that glucose transporter 1 (GLUT1) and hypoxia-inducible factor 1α (HIF-1α) are overexpressed in various malignancies and that they correlate with the maximum standard uptake values (SUVmax) on 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) and poor prognosis. In this study, we aim to evaluate the relationship between the SUVmax, GLUT1, and HIF-1α expression with primary tumor size, histological type, lymph node metastases, and patient survival. Of the 48 patients with non-small-cell lung cancer, those with squamous cell carcinomas (SCCs) had significantly higher GLUT1 and HIF-1α immunohistochemical expressions in comparison to adenocarcinomas (ACs), while there was no statistically significant difference in FDG accumulation between them. No significant correlation was noted between either GLUT1 or HIF-1α protein expression and FDG uptake and overall survival. However, an analysis of tumor transcriptomics showed a significant difference in overall survival depending on mRNA expression; patients with SCC and high levels survived longer compared to those with low levels, while patients with AC and low levels had a higher average survival time than those with high levels. Further studies are needed to determine the prognostic value of the expression of these factors depending on the histologic type.

Citing Articles

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review.

Zhu B, Cheng L, Huang B, Liu R, Ren B Medicine (Baltimore). 2024; 103(44):e40273.

PMID: 39496001 PMC: 11537650. DOI: 10.1097/MD.0000000000040273.


Global transcriptomic network analysis of the crosstalk between microbiota and cancer-related cells in the oral-gut-lung axis.

Otalora-Otalora B, Payan-Gomez C, Lopez-Rivera J, Pedroza-Aconcha N, Aristizabal-Guzman C, Isaza-Ruget M Front Cell Infect Microbiol. 2024; 14:1425388.

PMID: 39228892 PMC: 11368877. DOI: 10.3389/fcimb.2024.1425388.


Predictors for acute exacerbation of interstitial pneumonia following lung cancer surgery: a multicenter study.

Yin L, Xu R, Liu X, Fu L, Qiang G BMC Pulm Med. 2024; 24(1):377.

PMID: 39090591 PMC: 11295603. DOI: 10.1186/s12890-024-03177-5.


Differential expression of and its downstream target in the main subtypes of renal cell carcinoma and their impact on patient survival.

Strikic A, Kokeza J, Ogorevc M, Kelam N, Vukoja M, dolonga P Front Oncol. 2023; 13:1287239.

PMID: 38053655 PMC: 10694430. DOI: 10.3389/fonc.2023.1287239.

References
1.
Medina R, Owen G . Glucose transporters: expression, regulation and cancer. Biol Res. 2002; 35(1):9-26. DOI: 10.4067/s0716-97602002000100004. View

2.
Bao Y, Zhong J, Shen L, Dai L, Zhou S, Fan J . Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway. J Cell Mol Med. 2022; 26(10):2881-2894. PMC: 9907005. DOI: 10.1111/jcmm.17303. View

3.
Sowa T, Menju T, Chen-Yoshikawa T, Takahashi K, Nishikawa S, Nakanishi T . Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2016; 6(1):288-297. PMC: 5269694. DOI: 10.1002/cam4.991. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

5.
Finger E, Giaccia A . Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010; 29(2):285-93. PMC: 4012531. DOI: 10.1007/s10555-010-9224-5. View